Endocrine & Metabolic Drugs PNLE Questions
Introduction
The live inventory contains 48 original PNLE-style practice questions for Endocrine & Metabolic Drugs. It covers insulin, diabetes therapies, thyroid and adrenal drugs, and non-glycemic endocrine or metabolic medications.
Practice centers on matching a drug effect with the patient’s assessment, identifying a serious adverse effect, choosing the safest immediate nursing action, interpreting medication-related changes in glucose or electrolytes, and teaching precautions. The scope includes injection-site changes, steroid stress adjustment, antithyroid safety, SGLT2-associated euglycemic ketoacidosis, diabetes insipidus therapy, and medication use in hyperkalemia. Contraception and fertility agents are outside this page and belong in Reproductive Drugs.
NP7 Pharmacology is a cross-cutting Tangerine practice area integrated across relevant competencies in the official five-subject PNLE TOS. Under the 2025 Enhanced TOS, this lens does not receive a guaranteed microtopic weight. Use it to build transferable medication-safety reasoning rather than to predict an exam-form count.
Key concepts
- Match the drug to its physiologic effect
Recognize: Insulin lowers glucose and may shift potassium into cells; dextrose may accompany insulin for a different safety purpose.
Decide: Link the order to glucose, potassium, meal status, symptoms, and intended outcome before administration.
Avoid: Treating diabetes medicines as interchangeable or assuming dextrose removes total-body potassium. - Interpret insulin-site changes
Recognize: Repeated injections can produce firm or altered tissue and unpredictable absorption.
Decide: Inspect sites, rotate according to teaching, and avoid damaged areas.
Avoid: Using one comfortable site repeatedly or dismissing site changes as cosmetic. - Screen for dangerous diabetes-drug complications
Recognize: SGLT2 inhibition may precede ketoacidosis with nausea, vomiting, abdominal pain, malaise, or rapid breathing despite no marked hyperglycemia; sulfonylureas can cause hypoglycemia, with alcohol adding risk.
Decide: Assess symptoms, intake, glucose, and indicated ketone or acid-base findings; treat suspected hypoglycemia promptly.
Avoid: Using near-normal glucose to dismiss ketoacidosis or minimizing recurrent hypoglycemia. - Separate antithyroid toxicity from replacement excess
Recognize: PTU toxicity includes agranulocytosis and hepatic injury; levothyroxine excess may cause tachycardia, tremor, or heat intolerance.
Decide: Report fever, sore throat, jaundice, or excess-replacement cues and follow instructions for evaluation or holding therapy.
Avoid: Calling these findings minor or telling the patient to self-adjust. - Protect patients receiving glucocorticoids
Recognize: Glucocorticoids can raise glucose, mask infection, irritate the stomach, and suppress adrenal response; stress can increase steroid needs.
Decide: Monitor glucose and infection cues, follow administration precautions, and use the prescriber’s stress-dose plan.
Avoid: Abrupt discontinuation or independent dose changes. - Monitor water-balance therapy
Recognize: Diabetes insipidus therapy reduces water loss; headache, confusion, weight gain, or falling urine output can signal excess effect.
Decide: Trend intake and output, weight, neurologic status, and ordered sodium results, then escalate changes.
Avoid: Judging response from one urine measurement. - Use the correct sequence in catecholamine excess
Recognize: In pheochromocytoma crisis, catecholamine-driven vasoconstriction makes blockade sequence safety-critical.
Decide: When both are ordered, establish alpha-adrenergic blockade before beta-adrenergic blockade.
Avoid: Starting beta blockade first or treating sequence as a memorization detail.
What to expect on the PNLE
Question forms in the inventory support several kinds of nursing work: recognizing an adverse effect, selecting a medication or sequence, prioritizing an assessment, applying a teaching point, and interpreting a response after therapy. Titles involving insulin sites, steroid stress, PTU, SGLT2 inhibition, diabetes insipidus, levothyroxine, sulfonylureas, hyperkalemia, and pheochromocytoma show that the learner must connect pharmacology to assessment and action rather than recall a drug name alone.
The live distribution is 19 easy, 25 medium, and 4 hard questions. Its Bloom distribution is 18 remembering, 3 understanding, 21 applying, 3 analyzing, and 3 evaluating, so practice should include direct identification as well as decisions based on clinical cues. These figures describe the supplied inventory, not a promised exam blueprint.
- Recognition: Identify a class, intended effect, or serious adverse reaction from a cue.
- Application: Choose the safest next nursing action, monitoring priority, or patient instruction.
- Analysis: Compare similar presentations, such as drug toxicity versus the underlying endocrine disorder, and connect findings to mechanism.
- Evaluation: Judge whether a proposed action is safe, complete, and consistent with the medication’s risk profile.
Exact topic distribution varies by exam form. Keep adjacent practice separate when the decision depends mainly on reproductive agents, cardiovascular or renal drugs, or GI and hepatic drugs, then integrate those areas during mixed sets.
Study tips
- Start with diagnostic practice. Complete a set from the Endocrine & Metabolic Drugs inventory without notes. Record your answer, confidence, the clinical cue you used, and the decision you made.
- Use focused retrieval. For each weak area, recall the drug effect, danger signs, first nursing check, monitoring needs, and patient teaching before reopening your notes. Make this comparison grid yourself:Medication or class | intended effect | danger cue | first nursing check | teaching point
Insulin | glucose or potassium effect | hypoglycemia | glucose and meal status | site rotation
PTU | thyroid suppression | fever or jaundice | infection and liver cues | reporting precautions
Glucocorticoid | replacement or suppression | hyperglycemia or infection | glucose and stress plan | do not stop abruptly
SGLT2 inhibitor | glucose lowering | ketoacidosis symptoms | symptoms, glucose, indicated ketones | seek evaluation - Review rationales and errors. For every missed item, explain why the best option fits the mechanism and safety priority, then state why each competing option is less safe. Label the error as recall, mechanism, prioritization, or medication teaching.
- Retry with spacing. Reattempt missed questions after a later study session, then explain the decision without looking at the rationale. Keep a short list of cues that still trigger hesitation.
- Finish with mixed timed practice. Mix endocrine and metabolic drugs with Reproductive Drugs, Cardiovascular & Renal Drugs, and GI & Hepatic Drugs. After timing ends, classify each item as remembering, understanding, applying, analyzing, or evaluating and review the reasoning, not only the score.
Common mistakes to avoid
- Using a near-normal glucose result to rule out SGLT2-associated ketoacidosis. The safety cue is the symptom cluster, including gastrointestinal symptoms, malaise, or abnormal breathing. Evaluate the broader clinical picture and indicated ketone or acid-base findings.
- Making an insulin decision from glucose alone. Meal status, the ordered insulin purpose, symptoms, potassium, and the treatment plan can change the priority. Verify the order and assess the patient before administering, holding, or teaching about therapy.
- Missing early PTU toxicity. Fever or sore throat can signal agranulocytosis, while jaundice or dark urine can signal hepatic injury. Prompt reporting and evaluation are safer than continuing routine teaching without escalation.
- Stopping ongoing glucocorticoid therapy abruptly. Suppressed adrenal response creates a safety concern during interruption or physiologic stress. Follow the individualized prescriber plan for continuation, adjustment, and urgent assessment.
- Choosing beta blockade before alpha blockade in pheochromocytoma crisis. The sequence protects against worsening unopposed vasoconstriction. When both therapies are ordered, verify that alpha-adrenergic blockade is established first.
- Forgetting the follow-up after insulin and dextrose for hyperkalemia. This treatment shifts potassium into cells temporarily and does not remove total-body potassium. Reassess glucose, cardiac rhythm, potassium, and the response plan according to protocol.
Try a question
A real Endocrine & Metabolic Drugs question from our bank. Give it a shot.
A diabetic patient has developed fatty lumps at insulin injection sites. What is the main problem associated with injecting insulin into these areas?
Fatty lumps at insulin injection sites are known as lipohypertrophy. This is a common complication in patients who repeatedly inject insulin into the same area without rotating sites. Lipohypertrophy is characterized by the accumulation of fatty tissue at the site of injection due to the local anabolic effects of insulin.
Injecting insulin into areas of lipohypertrophy causes unpredictable insulin absorption. The expanded, fibrous, and often less-vascularized tissue alters the pharmacokinetics of insulin, leading to erratic absorption rates. Sometimes insulin is absorbed more slowly, reducing effectiveness, while at other times, it can be absorbed unpredictably and quickly, increasing the risk of hypo- or hyperglycemia. This variability makes blood glucose control difficult in diabetic patients and can lead to unstable glycemic patterns. This is why rotation of injection sites is a critical nursing responsibility when educating patients on insulin therapy.
Let’s review each answer choice:
| Option | Analysis |
|---|---|
| A. It causes unpredictable insulin absorption. | Correct. Lipohypertrophy disrupts normal insulin uptake, leading to erratic blood glucose management. This is the main clinical problem associated with repeated injections into affected areas. |
| B. It leads to hypoglycemia. | Incorrect. While unpredictable absorption from lipohypertrophy could increase risk for both hypo- and hyperglycemia, the key issue is that absorption is variable—not always leading to hypoglycemia. |
| C. It increases the risk of local infection. | Incorrect. Lipohypertrophy itself is not primarily associated with infection. Infections are more likely if sterile technique is not followed, but the fatty lump does not inherently increase infection risk. |
| D. It enhances insulin effectiveness. | Incorrect. In fact, insulin absorption is typically reduced or erratic in lipohypertrophic tissue, making glycemic control more difficult instead of more effective. |
Clinical Pearl: Teach patients to routinely rotate insulin injection sites within each anatomical area (abdomen, arm, thigh) to prevent lipohypertrophy and ensure more predictable insulin absorption.
Key Nursing Concepts: Patient education on site rotation, assessment of injection sites at each visit, and documentation are vital. This question tests your understanding of pathophysiology (tissue response to repeated insulin) and application of evidence-based insulin injection guidelines.
Memory Aid: 'Lumpy sites, unpredictable bites'—injecting into lumps leads to irregular insulin “bites” into bloodstream.
- Silvestri, L. A. (2017). Saunders Comprehensive Review for the NCLEX-RN Examination (7th ed.). Elsevier.
More Endocrine & Metabolic Drugs questions
46 questions available. Sign up to practice all of them.
A patient with adrenal insufficiency is scheduled for surgery. What should the nurse anticipate regarding the patient's steroid medication?
A nurse is monitoring a patient who started propylthiouracil (PTU) for hyperthyroidism two months ago. The patient reports a persistent sore throat. Which complication should the nurse suspect?
An SGLT2-inhibitor user has nausea, abdominal pain, fruity breath, glucose 178 mg/dL, and high anion-gap acidosis. Which interpretation is safest?
References and further reading
- PRC Enhanced Table of Specifications for the Nurses Licensure Examination official
The current public competency and cognitive-level blueprint, effective from the November 2025 NLE onward. - Tangerine Prep PNLE Reviewer question bank
The live source for the published question count, question previews, rationales, and inventory distributions on this page.
How this page is built
The counts and distributions on this page come from Tangerine Prep's live published question bank. The source inventory was last updated on August 12, 2026.
The questions are original PNLE-style practice items, not recalled or leaked board questions. Topic scope follows Tangerine's pedagogical taxonomy and is mapped to the PRC 2025 Enhanced Table of Specifications, effective from the November 2025 NLE onward. Exact topic distribution varies by exam form.